Full Press Release Details
Melbourne (Australia) and Indianapolis, IN (U.S.) | 30 May 2025
Telix today announces four accepted abstracts (three presentations) featuring the Company’s investigational therapeutic radiopharmaceutical programs at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from today, May 30, through June 3, 2025.
Scott Tagawa MD, Professor of Medicine & Urology Weill Cornell Medicine (NY) will present Telix’s ProstACT Global study of TLX591 (lutetium Lu 177 rosopatamab tetraxetan), the first Phase 3 trial to evaluate the radio antibody-drug conjugate (rADC) approach in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer (mCRPC).
Darren Feldman, MD, Medical Oncologist at Memorial Sloan Kettering Cancer Center (NY) will present the Phase 2 STARLITE-2 investigator-initiated trial (IIT) of Telix’s carbonic anhydrase IX (CAIX)-targeting therapy candidate, TLX250 ( 177 Lu-girentuximab), in combination with nivolumab immunotherapy in clear cell renal cell carcinoma (ccRCC), the most common and one of the most aggressive forms of kidney cancer.
Eric Jonasch, MD, Professor at MD Anderson Cancer Center (TX) will present the Phase 1b/2 STARLITE-1 IIT of TLX250 in combination with cabozantinib and nivolumab in treatment naïve patients with advanced ccRCC.
Telix’s CUPID proof-of-concept targeted alpha therapy study of TLX592 in patients with advanced prostate cancer has also been accepted for online publication only.
Visit booth #13121 to learn about Telix’s extensive theranostic pipeline in urologic oncology, neuro-oncology, musculoskeletal oncology and hematologic oncology, our investigational pan-cancer programs, associated medical technologies, and opportunities for collaboration.
ASCO presentation details are as follows (all times CDT):
Title: STARLITE-2, a Phase 2 study of nivolumab plus 177 Lu-labeled anti–CAIX monoclonal antibody girentuximab ( 177 Lu-girentuximab, TLX250) in patients with advanced ccRCC
Presenter: Darren Feldman MD, Memorial Sloan Kettering Cancer Center
Date and Time: Monday June 2 | 9:00 AM – 12:00 PM
Session: Genitourinary Cancer – Kidney and Bladder
Abstract ID : TPS4612 (Poster Board: 411b)
ClinicalTrials.gov ID: NCT05239533
Title: ProstACT Global, a Phase 3 study of 177 Lu-rosopatamab tetraxetan (TLX591) plus standard of care vs. standard of care alone in patients with mCRPC
Presenter: Scott Tagawa MD, Weill Cornell Medicine
Date and Time: Monday June 2 | 9:00 AM – 12:00 PM
Session: Genitourinary Cancer – Prostate, Testicular, and Penile
Abstract ID : TPS5126 (Poster Board: 317a)
ClinicalTrials.gov ID: NCT06520345
Title: STARLITE-1, a Phase 1b/2 study of combination 177 Lu-girentuximab (TLX250) plus cabozantinib and nivolumab in treatment naive patients with advanced ccRCC
Presenter: Eric Jonasch MD, MD Anderson Cancer Center
Date and Time: Monday June 2 | 9:00 AM – 12:00 PM
Session: Genitourinary Cancer – Kidney and Bladder
Abstract ID : TPS4611 (Poster Board: 411a)
ClinicalTrials.gov ID: NCT05663710
TLX591, TLX592 and TLX250 have not received a marketing authorization in any jurisdiction and are for investigational use only.